Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.

Abstract

PURPOSE:

To determine biologic differences, if any, between presurgical endocrine treatment with an aromatase inhibitor (vorozole) and tamoxifen in patients with postmenopausal primary breast cancer.

PATIENTS AND METHODS:

Randomization was to 12 weeks of 2.5 mg of vorozole per day or 20 mg of tamoxifen per day, both orally. Clinical response was assessed monthly together with serum sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogens (E1, E2, and E1S), lipids, insulin-like growth factor-1 (IGF-1), and bone metabolites (CrossLaps CTx). Tissue samples for Ki67, apoptotic index (AI), estrogen receptor, and progesterone receptor were collected at 0, 2, and 12 weeks.

RESULTS:

Ki67 fell by 58% and 43% (means) at 2 weeks in the vorozole and tamoxifen patients, respectively (P =.13). In the vorozole group, the correlations of proportional changes in Ki67 at 2 weeks with tumor volume changes and clinical response at 12 weeks were not significant (P =.09) and marginally significant (P =.04), respectively. Serum lipids did not differ between groups. Serum levels of EI, E2, and E1S were suppressed markedly by vorozole, whereas levels of SHBG increased and LH and FSH fell significantly with tamoxifen. IGF-1 levels fell significantly with tamoxifen (P =.001) compared with the nonsignificant rise with vorozole. Twelve-week CTx values fell by 19% with tamoxifen (P =.006) and rose by 11% with vorozole (P =.15).

CONCLUSION:

The correlation with vorozole of Ki67 with volume and clinical response supports this as an intermediate marker. The nonsignificant effects on bone and lipid metabolism by the aromatase inhibitor may be important to consider for adjuvant and potential prevention strategies.

• Authors: Catherine L Harper-Wynne, Nigel P M Sacks, Karyn Shenton, Fiona A MacNeill, Paul Sauven, Ian J Laidlaw, Zen Rayter, Stephanie Miall, Angela Howes, Janine Salter, Margaret J Hills, Frances M Lowe, Roger A'Hern, Nazar Nasiri, Debbie Doody, Jhangir Iqbal, Mitchell Dowsett
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 20 Issue 4 Pg. 1026-35 (Feb 15 2002) ISSN: 0732-183X [Print] United States
• PMID: 11844826 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Hormonal
• Biomarkers, Tumor
• Enzyme Inhibitors
• Ki-67 Antigen
• Receptors, Estrogen
• Receptors, Progesterone
• Triazoles
• Tamoxifen
• vorozole
• Luteinizing Hormone
• Follicle Stimulating Hormone

Topics

• Administration, Oral
• Aged
• Antineoplastic Agents, Hormonal (administration & dosage, pharmacology)
• Biomarkers, Tumor (analysis)
• Breast Neoplasms (drug therapy, pathology)
• Enzyme Inhibitors (administration & dosage, pharmacology)
• Female
• Follicle Stimulating Hormone (analysis)
• Humans
• Ki-67 Antigen (analysis)
• Luteinizing Hormone (analysis)
• Middle Aged
• Postmenopause
• Receptors, Estrogen (analysis)
• Receptors, Progesterone (analysis)
• Tamoxifen (administration & dosage, pharmacology)
• Triazoles (administration & dosage, pharmacology)